Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...

Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

(Reuters) -Novavax beat Wall Street expectations for third-quarter revenue on Thursday, helped by milestone payments tied to ...

Wondering if Novavax is a hidden bargain or just another biotech roller coaster? You are not alone, and getting to the bottom of its real value is more important than ever. Despite plenty of buzz, ...

Novavax raised its full-year 2025 revenue framework, now expecting adjusted total revenue between $1.04 billion and $1.06 ...

Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 as the biotech awaits key product launches from its partnership with ...

Novavax (NVAX) stock in focus as the company boosts 2025 revenue outlook after better than expected Q3 revenue driven by ...

Novavax is throwing marketing muscle behind its bid to capture a piece of the fall COVID-19 booster vaccine market. Having seen mRNA vaccines dominate the market, the biotech wants the public to know ...

The Food and Drug Administration announced Tuesday it had authorized Novavax's updated COVID-19 vaccine, adding a third option for Americans ages 12 and older looking for a new shot this fall and ...

On Oct. 3, the Food and Drug Administration (FDA) authorized the updated COVID-19 vaccine by Novavax for people ages 12 and older. The Centers for Disease Control and Prevention and its advisory panel ...

Novavax was an early coronavirus vaccine favorite but fell behind and missed out on the biggest revenue opportunity. Now it may enter the fall vaccine market later than rivals Pfizer and Moderna.